MedTech I.Q.

The Cutting Edge of Medical Technology Content, Community & Collaboration


The Advanced Medical Technology Association (AdvaMed) announced that it has established a new division - AdvaMed Dx - to focus solely on issues facing companies that manufacture in vitro diagnostic technologies. The division will function as an association within an association, while still having access to, and support from, the broader resources offered by AdvaMed.

"In vitro diagnostics exemplify the promise of better patient care in this exciting era of the life sciences. Having an advocacy organization that solely focuses on the unique regulatory, reimbursement and other policy interests of in vitro diagnostics companies will help this vitally important sector continue to grow and thrive, helping patients better detect and fight disease," said Stephen J. Ubl, president and CEO of AdvaMed.

AdvaMed Dx will be governed by an 18-member Board of Directors and an 8-member Executive Committee, comprised of CEOs from in vitro diagnostics companies. The Board of Directors will be chaired by Scott Garrett, Beckman Coulter's chairman, president and chief executive officer...

... Some of the issues of particular importance that AdvaMed Dx will focus on include establishment of a modernized risk-based approach to the regulation of in vitro diagnostics to support timely patient access to safe and effective tests. It will also focus on reforming the antiquated Medicare payment system for clinical laboratory diagnostic tests to fully recognize the value of new tests, especially the new generation of molecular diagnostic tests...

Read on at:

Views: 0

© 2021   Created by CC-Conrad Clyburn-MedForeSight.   Powered by

Badges  |  Report an Issue  |  Terms of Service